Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes

Hypomethylating agents (HMAs) are effective therapies in myelodysplastic syndromes (MDS), but allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way to cure MDS. According to the current literature, it is difficult to confirm whether HMAs bridging therapy is beneficial for MD...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Liu, Jia, Menglu, Sun, Ling, Tian, Wenliang, Tang, Ping, Jiang, Zhongxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505317/
https://www.ncbi.nlm.nih.gov/pubmed/33866494
http://dx.doi.org/10.1007/s10238-021-00712-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505317/
https://www.ncbi.nlm.nih.gov/pubmed/33866494
http://dx.doi.org/10.1007/s10238-021-00712-0

Ejemplares similares